Genetics Study of In-stent Restenosis (ISR)
Status
Conditions
Details and patient eligibility
About
The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).
Full description
Although drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents, the restenosis rate is still high in the high-risk group. G protein plays important roles in the signal transduction leading to vascular smooth muscle proliferation. The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients who underwent follow-up angiography. All the patients must had been implanted with DES during the last two years.
Exclusion criteria
- For the non-ISR group, the patients underwent follow-up angiography less than 6 months away from stent implanting.
Trial design
300 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Yamei Xu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal